Opus Genetics, Inc. (IRD) vs Relmada Therapeutics, Inc. (RLMD)
Opus Genetics, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Opus Genetics, Inc. and Relmada Therapeutics, Inc. are of similar size ($406.4M and $405.2M). Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −1,091.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Relmada Therapeutics, Inc. leads on 7 and Opus Genetics, Inc. on 5.
Valuation
Profitability
| Metric | IRD | RLMD | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 0.00% | 65.16% |
| Operating margin | (513.47%) | 0.00% | 0.00% |
| Net margin | (1,091.82%) | 0.00% | 0.00% |
| Free cash flow margin | (412.61%) | 0.00% | 0.00% |
| Return on equity | (4,796.52%) | (55.66%) | (57.72%) |
| Return on assets | (163.50%) | (51.57%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack